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Abstract: Enzymes are biocatalysts evolved in nature to achieve
the speed and coordination of nearly all the chemical reactions that
define cellular metabolism necessary to develop and maintain life.
The application of biocatalysis is growing rapidly, since enzymes
offer potential for many exciting applications in industry. The ad-
vent of whole genome sequencing projects enabled new approaches
for biocatalyst development, based on specialised methods for en-
zyme heterologous expression and engineering. The engineering of
enzymes with altered activity, specificity and stability, using site-
directed mutagenesis and directed evolution techniques are now
well established. Over the last decade, enzyme immobilisation has
become important in industry. New methods and techniques for en-
zyme immobilisation allow for the reuse of the catalysts and the
development of efficient biotechnological processes. This chapter
reviews advances in enzyme technology as well as in the techniques
and strategies used for enzyme production, engineering and immo-
bilisation and discuss their advantages and disadvantages.
PREFACE
Enzymes are proteins with powerful catalytic functions. They
increase reaction rates sometimes by as much as one million
fold, but more typically by about one thousand fold. Catalytic
activity can also be shown, to a limited extent, by biological
molecules other than the ‘classical’ enzymes. For example, an-
tibodies raised to stable analogues of the transition states of
a number of enzyme-catalysed reactions can act as effective
Food Biochemistry and Food Processing, Second Edition. Edited by Benjamin K. Simpson, Leo M.L. Nollet, Fidel Toldra´, Soottawat Benjakul, Gopinadhan Paliyath and Y.H. Hui.
C© 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc.
125
P1: SFK/UKS P2: SFK
BLBS102-c07 BLBS102-Simpson March 21, 2012 11:12 Trim: 276mm X 219mm Printer Name: Yet to Come
126 Part 2: Biotechnology and Enzymology
catalysts for those reactions (Hsieh-Wilson et al. 1996). In ad-
dition, RNA molecules can also act as a catalyst for a number
of different types of reactions (Lewin 1982). These antibod-
ies and RNA catalysts are known as abzymes and ribozymes,
respectively.
Enzymes have a number of distinct advantages over conven-
tional chemical catalysts. Among these are their high productiv-
ity, catalytic efficiency, specificity and their ability to discrim-
inate between similar parts of molecules (regiospecificity) or
optical isomers (stereospecificity). Enzymes, in general, work
under mild conditions of temperature, pressure and pH. This
advantage decreases the energy requirements and therefore re-
duces the capital costs. However, there are some disadvantages
in the use of enzymes, such as high cost and low stability. These
shortcomings are currently being addressed mainly by employ-
ing protein engineering approaches using recombinant DNA
technology (Stemmer 1994, Ke and Madison 1997). These ap-
proaches aim at improving various properties such as thermosta-
bility, specificity and catalytic efficiency. The advent of designer
biocatalysts enables production of not only process-compatible
enzymes, but also novel enzymes able to catalyse new or
unexploited reactions (Schmidt-Dannert et al. 2000, Umeno and
Arnold 2004). This is just the start of the enzyme technology era.
ENZYME STRUCTURE AND MECHANISM
Nomenclature and Classification of Enzymes
Enzymes are classified according to the nature of the reaction
they catalyse (e.g. oxidation/reduction, hydrolysis, synthesis,
etc.) and sub-classified according to the exact identity of their
substrates and products. This nomenclature system was estab-
lished by the Enzyme Commission (a committee of the Inter-
national Union of Biochemistry). According to this system, all
enzymes are classified into six major classes:
1. Oxidoreductases, which catalyse oxidation–reduction reac-
tions.
2. Transferases, which catalyse group transfer from one
molecule to another.
3. Hydrolases, which catalyse hydrolytic cleavage of C–C,
C–N, C–O, C–S or O–P bonds. These are group transfer
reactions but the acceptor is always water.
4. Lyases, which catalyse elimination reactions, resulting in
the cleavage of C–C, C–O, C–N, C–S bonds or the for-
mation of a double bond, or conversely adding groups to
double bonds.
5. Isomerases, which catalyse isomerisation reactions, e.g.,
racemisation, epimerisation, cis-trans-isomerisation, tau-
tomerisation.
6. Ligases, which catalyse bond formation, coupled with the
hydrolysis of a high-energy phosphate bond in ATP or a
similar triphosphate.
The Enzyme Commission system consists of a numerical clas-
sification hierarchy of the form ‘E.C. a.b.c.d’ in which ‘a’ rep-
resents the class of reaction catalysed and can take values from
1 to 6 according to the classification of reaction types given
above. ‘b’ denotes the sub-class, which usually specifies more
precisely the type of the substrate or the bond cleaved, e.g. by
naming the electron donor of an oxidation–reduction reaction or
by naming the functional group cleaved by a hydrolytic enzyme.
‘c’ denotes the sub-subclass, which allows an even more precise
definition of the reaction catalysed. For example, sub-subclasses
of oxidoreductases are denoted by naming the acceptor of the
electron from its respective donor. ‘d’ is the serial number of the
enzyme within its sub-subclass. An example will be analysed.
The enzyme that oxidises d-glucose using molecular oxygen
catalyses the following reaction:
O
O
O
O
O
+ O2
Glucose oxidase
β-D-Glucose D-Glucono-1,5-lactone
+ H2O2
O
O
O
O
O
OO
Scheme 7.1.
Hence, its systematic name is d-glucose: oxygen oxidoreduc-
tase, and its systematic number is EC 1.1.3.4.
The systematic names are often quite long, and therefore,
short trivial names along with systematic numbers are often
more convenient for enzyme designation. These shorter names
are known as recommended names. The recommended names
consist of the suffix ‘–ase’ added to the substrate acted on. For
example for the enzyme mentioned above, the recommended
name is glucose oxidase.
It should be noted that the system of nomenclature and classi-
fication of enzymes is based only on the reaction catalysed and
takes no account of the origin of the enzyme, that is from the
species or tissue it derives.
Basic Elements of Enzyme Structure
The Primary Structure of Enzyme
Enzymes are composed of l-α-amino acids joined together by
a peptide bond between the carboxylic acid group of one amino
acid and the amino group of the next.
R1 R2 R1 HH⏐⏐
H2O
⏐⏐⏐
H2N⎯C⎯ COOH H2N⎯C ⎯COOH H2N ⎯C ⎯C⎯N⎯C ⎯ COOH⏐⏐⏐ = ⏐
R2OHHH
Peptitde bond
Scheme 7.2.
There are 20 common amino acids in proteins, which are spec-
ified by the genetic code; in rare cases, others occur as the prod-
ucts of enzymatic modifications after translation. A common
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feature of all 20 amino acids is a central carbon atom (Cα) to
which a hydrogen atom, an amino group (–NH2) and a carboxy
group (–COOH) are attached. Free amino acids are usually zwit-
terionic at neutral pH, with the carboxyl group deprotonated and
the amino group protonated. The structure of the most common
amino acids found in proteins is shown in Table 7.1. Amino
acids can be divided into four different classes depending on the
structure of their side chains, which are called R groups: non-
polar, polar uncharged, negatively charged (at neutral pH) and
positively charged (at neutral pH; Richardson 1981). The prop-
erties of the amino acid side chains determine the properties of
the proteins they constitute. The formation of a succession of
peptide bonds generates the ‘main chain’ or ‘backbone’.
The primary structure of a protein places several constrains
on how it can fold to produce its three-dimensional structure
(Cantor 1980, Fersht 1999). The backbone of a protein consists
of a carbon atom Cα to which the side chain is attached, a NH
group bound to Cα and a carbonyl group C = O, where the
carbon atom C is attached to Cα (Fig. 7.1) The peptide bond is
planar since it has partial (∼40%) double bond character with
π electrons shared between the C–O and C–N bonds (Fig. 7.1).
The peptide bond has a trans-conformation, that is the oxygen of
the carbonyl group and the hydrogen of the NH group are in the
trans position; the cis conformation occurs only in exceptional
cases (Richardson 1981).
Enzymes have several ‘levels’ of structure. The protein’s se-
quence, that is the order of amino acids, is termed as its ‘primary
structure’. This is determined by the sequence of nucleotide
bases in the gene that codes for the protein. Translation of the
mRNA transcript produces a linear chain of amino acids linked
together by a peptide bond between the carboxyl carbon of the
(A)
(B)
Figure 7.1. (A) The amide bond showing delocalisation of
electrons. (B) A tripeptide unit of a polypeptide chain showing the
planar amide units and the relevant angles of rotation about the
bonds to the central α-carbon atom.
first amino acid and the free amino group of the second amino
acid. The first amino acid in any polypeptide sequence has a free
amino group and the terminal amino acid has a free carboxyl
group. The primary structure is responsible for the higher levels
of enzyme’s structure and therefore for the enzymatic activity
(Richardson 1981, Price and Stevens 1999).
The Three-Dimensional Structure of Enzymes
Enzymes are generally very closely packed globular structures
with only a small number of internal cavities, which are normally
filled by water molecules. The polypeptide chains of enzymes
are organised into ordered, hydrogen bonded regions, known
as secondary structure (Andersen and Rost 2003). In these or-
dered structures, any buried carbonyl oxygen forms a hydro-
gen bond with an amino NH group. This is done by forming
α-helices and β-pleated sheets, as shown in Figure 7.2. The α-
helix can be thought of as having a structure similar to a coil or
spring (Surewicz and Mantsch 1988). The β-sheet can be visu-
alised as a series of parallel strings laid on top of an accordion-
folded piece of paper. These structures are determined by the
protein’s primary structure. Relatively small, uncharged, polar
amino acids readily organise themselves into α-helices, while
relatively small, non-polar amino acids form β-sheets. Proline is
a special amino acid because of its unique structure (Table 7.1).
Introduction of proline into the sequence creates a permanent
bend at that position (Garnier et al. 1990). Therefore, the pres-
ence of proline in an α-helix or β-sheet disrupts the secondary
structure at that point. The presence of a glycine residue confers
greater than normal flexibility on a polypeptide chain. This is
due to the absence of a bulky side chain, which reduces steric
hindrance.
Another frequently observed structural unit is the β-turn (Fang
and Shortle 2003). This occurs when the main chain sharply
changes direction using a bend composed of four successive
residues, often including proline and glycine. In these units,
the C = O group of residue i is hydrogen bonded to the NH of
residue i+3 instead of i+4 as in α-helix. Many different types of
β-turn have been identified, which differ in terms of the number
of amino acids and in conformation (e.g. Type I, Type II, Type
III; Sibanda et al. 1989).
The three-dimensional structure of a protein composed of
a single polypeptide chain is known as its tertiary structure.
Tertiary structure is determined largely by the interaction of
R groups on the surface of the protein with water and with
other R groups on the protein’s surface. The intermolecular non-
covalent attractive forces that are involved in stabilising the
enzyme’s structure are usually classified into three types: ionic
bonds, hydrogen bonds and van der Waals attractions (Matthews
1993). Hydrogen bonding results from the formation of hydro-
gen bridges between appropriate atoms; electrostatic bonds are
due to the attraction of oppositely charged groups located on
two amino acid side chains. Van der Waals bonds are gener-
ated by the interaction between electron clouds. Another im-
portant weak force is created by the three-dimensional structure
of water, which tends to force hydrophobic groups together in
order to minimise their disruptive effect on hydrogen-bonded
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Table 7.1. Names, Symbols (One Letter and Three Letters Code) and Chemical Structures of the 20 Amino Acids
Found in Proteins
Non-polar amino acids
Alanine Ala (A) CH3–CH–COOH
NH2
Valine Val (V)
CH–CH–COOH
NH2
H3C
H3C
Leucine Leu (L)
CH–CH2–CH–COOH
NH2
G2B
G2B
Isoleucine Ile (I)
CH–CH–COOH
NH2
H3C CH2
H3C
Methionine Met (M) CH3–S–CH2–CH–COOH
NH2
Tryptophan Trp (W) CH2–CH–COOH
NH2NH
Phenylalanine Phe (P) CH2–CH–COOH
NH2
Proline Pro (P)
COOH
HH
N
+
Polar uncharged amino acids
Glycine Gly (G) H–CH–COOH
NH2
Asparagine Asp (D) H2N–C–CH2–CH–COOH
NH2O
Glutamine Gln (Q) CH2CH2H2N C
O
COOHCH
NH2
Serine Ser (S) CH2HO COOHCH
NH2
Threonine Thr (T)
CH2
CH3
HO COOHCH
NH2
Cysteine Cys (C) CH2HS COOHCH
NH2
Tyrosine Tyr (Y) HO CH2 COOHCH
NH2
Negatively charged amino acids
Glutamate Glu (E) CH2CH2HOOC COOHCH
NH2
Aspartate Asn (N) CH2 COOHHOOC CH
NH2
Positively charged amino acids
Arganine Arg (R) CH2 CH2CH2HN COOHCH
NH2C NH
NH2
Lysine Lys (K) H2N COOH(CH2)4 CH
NH2
Histidine His (H) CH2 COOHCH
HN N: NH2
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(A)
(B)
Figure 7.2. Representation of α-helix and β-sheet. Hydrogen bonds are depicted by doted lines.
network of water molecules. Apart from the peptide bond, the
only other type of covalent bond involved in linking amino-
acids is the disulphide (–S–S–) bond, which can be formed
between two cysteine side-chains under oxidising conditions.
The disulphide bond contributes significantly to the structural
stability of an enzyme and more precisely in tertiary structural
stabilisation (see below for details; Matthews 1993, Estape et al.
1998).
Detailed studies have shown that certain combinations of α-
helices or β-sheet together with turns occur in many proteins.
These often-occurring structures have been termed motifs, or
super-secondary structure (Kabsch and Sander 1983, Adamson
et al. 1993). Examples of motifs found in several enzymes are
shown in Figure 7.3. These protein folds represent highly stable
structural units, and it is believed that they may form nucleating
centres in protein folding (Richardson 1981).
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βαβ
Figure 7.3. Common examples of motifs found in proteins.
Certain combinations of α-helices and β-sheets pack together
to form compactly folded globular units, each of which is called
protein domain with molecular mass of 15,000 to 20,000 Da
(Orengo et al. 1997). Domains may be composed of secondary
structure and identifiable motifs and therefore represent a higher
level of structure than motifs. The most widely used classifica-
tion scheme of domains has been the four-class system (Fig. 7.4;
Murzin et al. 1995). The four classes of protein structure are as
follows:
1. All-α-proteins, which have only α-helix structure.
2. All-β-proteins, which have β-sheet structure.
3. α/β-proteins, which have mixed or alternating segments of
α-helix and β-sheet structure.
4. α+β proteins, which have α-helix and β-sheet struc-
tural segments that do not mix but are separated along
the polypeptide chain.
While small proteins may contain only a single domain, larger
enzymes contain a number of domains. In fact, most enzymes
are dimers, tetramers or polymers of several polypeptide chains.
Each polypeptide chain is termed ‘subunit’ and it may be iden-
tical or different to the others. The side chains on each polypep-
tide chain may interact with each other, as well as with water
molecules to give the final enzyme structure. The overall or-
ganisation of the subunits is known as the quaternary struc-
ture and therefore the quaternary structure is a characteristic of
multi-subunit enzymes. The four levels of enzyme structure are
illustrated in Figure 7.5.
Theory of Enzyme Catalysis and Mechanism
In order for a reaction to occur, the reactant molecules must
possess sufficient energy to cross a potential energy barrier,
which is known as the activation energy (Fig. 7.6; Hackney
1990). All reactant molecules have different amounts of energy,
but only a small proportion of them have sufficient energy to
cross the activation energy of the reaction. The lower the activa-
tion energy, the more substrate molecules are able to cross the
activation energy. The result is that the reaction rate is increased.
Enzyme catalysis requires the formation of a specific re-
versible complex between the substrate and the enzyme. This
complex is known as the enzyme–substrate complex (ES) and
provides all the conditions that favour the catalytic event (Hack-
ney 1990, Marti et al. 2004). Enzymes accelerate reactions by
lowering the energy required for the formation of a complex of
reactants that is competent to produce reaction products. This
complex is known as the transition state complex of the reaction
and is characterised by lower free energy than it would be found
in the uncatalysed reaction.
E EP  ES ES E + S * P + 
Scheme 7.3.
The ES must pass to the transition state (ES*). The transition
state complex must advance to an enzyme–product complex (EP),
which dissociates to free enzyme and product (P). This reaction’s
pathway goes through the transition states TS1, TS2 and TS3.
The amount of energy required to achieve the transition state
is lowered; hence, a greater proportion of the molecules in the
population can achieve the transition state and cross the activa-
tion energy (Benkovic and Hammes-Schiffer 2003, Wolfenden
2003). Enzymes speed up the forward and reverse reactions
proportionately, so that they have no effect on the equilibrium
constant of the reactions they catalyse (Hackney 1990).
Substrate is bound to the enzyme by relatively weak non-
covalent forces. The free energy of interaction of the ES com-
plex ranges between −12 to −36 kJ/mole. The intermolecular
attractive forces between enzyme–substrate, in general, are of
three types: ionic bonds, hydrogen bonds and van der Waals
attractions.
Specific part of the protein structure that interacts with the
substrate is known as the substrate binding site (Fig. 7.7). The
substrate binding site is a three-dimensional entity suitably de-
signed as a pocket or a cleft to accept the structure of the substrate
in three-dimensional terms. The binding residues are defined as
any residue with any atom within 4 Å of a bound substrate. These
binding residues that participate in the catalytic event are known
as the catalytic-residues and form the active-site. According to
Bartlett et al. (Bartlett et al. 2002), a residue is defined as cat-
alytic if any of the following take place:
1. Direct involvement in the catalytic mechanism, for exam-
ple as a nucleophile.
2. Exerting an effect, that aids catalysis, on another residue or
water molecule, which is directly involved in the catalytic
mechanism.
3. Stabilisation of a proposed transition-state intermediate.
4. Exerting an effect on a substrate or cofactor that aids catal-
ysis, for example by polarising a bond that is to be broken.
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(A) (B)
(C) (D)
Figure 7.4. The four-class classification system of domains. (A) The α + β class (structure of glycyl-tRNA synthetase α-chain). (B) the all α
class (structure of the hypothetical protein (Tm0613) from Thermotoga maritima). (C) The α/β class (structure of glycerophosphodiester
phosphodiesterase). (D) The all β class (structure of allantoicase from Saccharomyces cerevisiae).
Despite the impression that the enzyme’s structure is static and
locked into a single conformation, several motions and confor-
mational changes of the various regions always occur (Hammes
2002). The extent of these motions depends on many factors, in-
cluding temperature, the properties of the solvating medium, the
presence or absence of substrate and product (Hammes 2002).
The conformational changes undergone by the enzyme play an
important role in controlling the catalytic cycle. In some en-
zymes, there are significant movements of the binding residues,
usually on surface loops, and in other cases, there are larger con-
formational changes. Catalysis takes place in the closed form and
the enzyme opens again to release the product. This favoured
model that explains enzyme catalysis and substrate interaction is
the so-called induced fit hypothesis (Anderson et al. 1979, Joseph
et al. 1990). In this hypothesis, the initial interaction between
enzyme and substrate rapidly induces conformational changes
in the shape of the active site, which results in a new shape of
the active site that brings catalytic residues close to substrate
bonds to be altered (Fig. 7.8). When binding of the substrate
to the enzyme takes place, the shape adjustment triggers catal-
ysis by generating transition-state complexes. This hypothesis
helps to explain why enzymes only catalyse specific reactions
(Anderson et al. 1979, Joseph et al. 1990). This basic cycle has
been seen in many different enzymes, including triosephosphate
isomerase, which uses a small hinged loop to close the active
site (Joseph et al. 1990) and kinases, which use two large lobes
moving towards each other when the substrate binds (Anderson
et al. 1979).
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Figure 7.5. Schematic representation of the four levels of protein
structure.
Coenzymes, Prosthetic Groups and Metal
Ion Cofactors
Non-protein groups can also be used by enzymes to affect catal-
ysis. These groups, called cofactors, can be organic or inorganic
and are divided into three classes: coenzymes, prosthetic groups
and metal ion cofactors (McCormick 1975). Prosthetic groups
are tightly bound to an enzyme through covalent bond. Coen-
zymes bind to enzyme reversibly and associate and dissociate
from the enzyme during each catalytic cycle and therefore may
be considered as co-substrates. An enzyme containing a cofactor
or prosthetic group is termed as holoenzyme. Coenzymes can be
broadly classified into three main groups: coenzymes that trans-
fer groups onto substrate, coenzymes that accept and donate
electrons and compounds that activate substrates (Table 7.2).
Metal ions such as Ca+2, Mg+2, Zn+2, Mn+2, Fe+2 and Cu+2
may in some cases act as cofactors. These may be bound to the
enzyme by simple coordination with electron-donating atoms
of side chains (imidazole of His, –SH group of Cys, carboxy-
late O− of Asp and Glu). In some cases, metals, such as Mg+2,
are associated with the substrate rather than the enzyme. For
example, Mg-ATP is the true substrate for kinases (Anderson
et al. 1979). In other cases, metals may form part of a prosthetic
group in which they are bound by coordinate bonds (e.g. heme;
Table 7.2) in addition to side-chain groups. Usually, in this case,
metal ions participate in electron transfer reactions.
Kinetics of Enzyme-Catalysed Reactions
The term enzyme kinetics implies a study of the velocity of an
enzyme-catalysed reaction and of the various factors that may
affect this (Moss 1988). An extensive discussion of enzyme
kinetics would stay too far from the central theme of this chapter,
but some general aspects will be briefly considered.
The concepts underlying the analysis of enzyme kinetics con-
tinue to provide significant information for understanding in vivo
function and metabolism and for the development and clinical
use of drugs aimed at selectively altering rate constants and in-
terfering with the progress of disease states (Bauer et al. 2001).
Central scope of any study of enzyme kinetics is knowledge of
the way in which reaction velocity is altered by changes in the
concentration of the enzyme’s substrate and of the simple math-
ematics underlying this (Wharton 1983, Moss 1988, Watson
and Dive 1994). As we have already discussed, the enzymatic
reactions proceed through an intermediate ES in which each
molecule of enzyme is combined, at any given instant during
the reaction, with one substrate molecule. The reaction between
enzyme and substrate to form the ES is reversible. Therefore,
the overall enzymatic reaction can be shown as
 E + P ES E + S 
k+1 k+2
k–1
Scheme 7.4.
where k+1, k−1 and k+2 are the respective rate constants. The re-
verse reaction concerning the conversion of product to substrate
is not included in this scheme. This is allowed at the beginning
of the reaction when there is no, or little, product present. In
1913, biochemists Michaelis and Menten suggested that if the
reverse reaction between E and S is sufficiently rapid, in com-
parison with the breakdown of ES complex to form product, the
latter reaction will have a negligible effect on the concentration
of the ES complex. Consequently, E, S and ES will be in equi-
librium, and the rates of formation and breakdown of ES will be
equal. On the basis of these assumptions Michaelis and Menten
produced the following equation:
v = Vmax · [S]
Km + [S]
This equation is a quantitative description of the relationship
between the rate of an enzyme-catalysed reaction (u) and the
concentration of substrate [S]. The parameters Vmax and Km are
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Figure 7.6. A schematic diagram showing the free energy profile of the course of an enzyme catalysed reaction involving the formation of
enzyme–substrate (ES) and enzyme–product (EP) complexes. The catalysed reaction pathway goes through the transition states TS1, TS2,
and TS3, with standard free energy of activation Gc, whereas the uncatalysed reaction goes through the transition state TSu with standard
free energy of activation Gu.
constants at a given temperature and a given enzyme concentra-
tion. The Km or Michaelis constant is the substrate concentration
at which v = Vmax/2 and its usual unit is M. The Km provides
us with information about the substrate binding affinity of the
enzyme. A high Km indicates a low affinity and vice versa (Moss
1988, Price and Stevens 1999).
The Vmax is the maximum rate of the enzyme-catalysed re-
action and it is observed at very high substrate concentrations
where all the enzyme molecules are saturated with substrate, in
the form of ES complex. Therefore
Vmax = kcat[Et]
where [Et] is the total enzyme concentration and kcat is the rate
of breakdown of the ES complex (k+2 in the equation), which
is known as the turnover number. kcat represents the maximum
number of substrate molecules that the enzyme can convert to
product in a set time. The Km depends on the particular en-
zyme and substrate being used and on the temperature, pH,
ionic strength, etc. However, note that Km is independent of the
enzyme concentration, whereas Vmax is proportional to enzyme
concentration. A plot of the initial rate (v) against initial substrate
concentration ([S]) for a reaction obeying the Michaelis–Menten
kinetics has the form of a rectangular hyperbola through the ori-
gin with asymptotes v = Vmax and [S] = −Km (Fig. 7.9A). The
term hyperbolic kinetics is also sometimes used to characterise
such kinetics.
There are several available methods for determining the pa-
rameters from the Michaelis–Menten equation. A better method
for determining the values of Vmax and Km was formulated by
Hans Lineweaver and Dean Burk and is termed the Lineweaver-
Burk (LB) or double reciprocal plot (Fig. 7.9B). Specifically, it
is a plot of 1/v versus 1/[S], according to the equation:
1
v
= Km
Vmax
· 1[S] +
1
Vmax
Such a plot yields a straight line with a slope of Km/Vmax.
The intercept on the 1/v axis is 1/Vmax and the intercept on the
1/[S] axis is −1/Km.
The rate of an enzymatic reaction is also affected by changes
in pH and temperature (Fig. 7.10). When pH is varied, the veloc-
ity of reaction in the presence of a constant amount of enzyme is
typically greatest over a relatively narrow range of pH. Since en-
zymes are proteins, they possess a large number of ionic groups,
which are capable of existing in different ionic forms (Labrou
et al. 2004a). The existence of a fairly narrow pH-optimum for
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Figure 7.7. The substrate binding site of maize glutathione
S-transferase. The binding residues are depicted as sticks, whereas
the substrate is depicted in a space fill model. Only Ser 11 is
involved directly in catalysis and is considered as catalytic residue.
Figure 7.8. A schematic representation of the induced fit
hypothesis.
most enzymes suggests that one particular ionic form of the
enzyme molecule, out of the many that it can potentially exist,
is the catalytically active one. The effect of pH changes on v
is reversible, except after exposure to extremes of pH at which
denaturation of the enzyme may occur.
The rate of an enzymatic reaction increases with increasing
temperature. Although there are significant variations from one
enzyme to another, on average, for each 10◦C rise in temper-
ature, the enzymatic activity is increased by an order of two.
After exposure of the enzyme to high temperatures (normally
greater that 65◦C), denaturation of the enzyme may occur and
the enzyme activity decreased. The Arrhenius equation
LogVmax = −Ea2,303RT + A
provides a quantitative description of the relationship between
the rate of an enzyme-catalysed reaction (Vmax) and the temper-
ature (T). Where Ea is the activation energy of the reaction, R
is the gas constant, and A is a constant relevant to the nature of
the reactant molecules.
The rates of enzymatic reactions are affected by changes in
the concentrations of compounds other than the substrate. These
modifiers may be activators, that is they increase the rate of
reaction or their presence may inhibit the enzyme’s activity. Ac-
tivators and inhibitors are usually small molecules or even ions.
Enzyme inhibitors fall into two broad classes: those causing ir-
reversible inactivation of enzymes and those whose inhibitory
effects can be reversed. Inhibitors of the first class bind cova-
lently to the enzyme so that physical methods of separating the
two are ineffective. Reversible inhibition is characterised by the
existence of equilibrium between enzyme and inhibitor (I):
E + I  EI
Scheme 7.5.
The equilibrium constant of the reaction, Ki, is given by the
equation:
Ki = [ES][E][I ]
Ki is a measure of the affinity of the inhibitor for the enzyme.
Reversible inhibitors can be divided into three main categories:
competitive inhibitors, non-competitive inhibitors and uncom-
petitive inhibitors. The characteristic of each type of inhibition
and their effect on the kinetic parameters Km and Vmax are shown
in Table 7.3.
Thermodynamic Analysis
Thermodynamics is the science that deals with energy. Chemi-
cal bonds store energy, as the subatomic particles are being at-
tracted and chemical reactions are occurred with energy changes.
Originally, thermodynamic laws were used to analyse and char-
acterise mechanical systems, but the kinetic molecular theory
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Table 7.2. The Structure of Some Common Coenzymes: Adenosine Triphosphate (ATP), Coenzyme A (CoA),
Flavin Adenine Dinucleotide (FAD), Nicotinamide Adenine Dinucleotide (NAD+) and Heam c
Cofactor Type of Reactions Catalysed Structure
Adenosine triphosphate (ATP) Phosphate transfer reactions (e.g. kinases)
Coenzyme A (CoA) Acyl transfer reactions (transferases)
Flavin adenine dinucleotide (FAD) Redox reactions (reductases)
Nicotinamide adenine dinucleotide
(NAD+)
Redox reactions (e.g. dehydrogenases)
Heam c Activate substrates
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Figure 7.9. (A) A plot of the initial rate (v) against initial substrate
concentration ([S]) for a reaction obeying the Michaelis-Menten
kinetics. The substrate concentration, which gives a rate of half the
maximum reaction velocity, is equal to the Km. (B) The
Lineweaver-Burk plot. The intercept on the 1/v axis is 1/Vmax, the
intercept on the 1/[S] axis is −1/Km and the slope is Km/Vmax.
(Eblin 1964) suggests that molecules are in constant motion,
which obey the same laws of mechanics as macroscopic objects.
Since enzymes are biomolecules, which catalyse chemical reac-
tions, they contribute to the energetic background of a chemical
system. As a result, enzymes are directly related to thermody-
namic parameters.
In this section, we will focus on the most representative ther-
modynamic parameters that are useful, in order to describe ex-
perimental data. The fundamental thermodynamic parameters
are the Helmholtz free energy (F), the entropy (S) and the en-
thalpy (H). Free energy (F) correlates the energy (E) of a system
with its entropy (S): F = E − TS, where T is the temperature.
The entropy (S) of a system is the range of its disorder and the
thermodynamic definition is (Rakintzis 1994) (the symbol q is
used to represent the amount of heat absorbed by a system):
S =
∫
q
T
dT ⇔ S = q ln(T )
Furthermore, enthalpy is a constitutive function of pressure
(P) and temperature (T), and energy (E) is a constitutive func-
Figure 7.10. Relationship of the activity–pH and
activity–temperature for a putative enzyme.
tion of volume (V) and temperature (T), respectively (Rakintzis
1994):
H = f (P, T )
dH =
[
∂H
∂P
]
T
dP +
[
∂H
∂T
]
P
dT
E = f (V, T )
dE =
[
∂E
∂V
]
T
dV +
[
∂E
∂T
]
V
dT
At this point, we have to emphasise that in biological systems,
a normal experiment deals with a constant pressure (atmospheric
pressure) and not with a constant volume. This means, that we
determine not a change of energy (E) of a studied body (e.g.
enzyme), but a change in its enthalpy: H = E + PV . However,
the quantity (PV) is considered insignificant in case that we study
a protein for instance, because the volume per molecule is too
small. Hence, there is no difference between H and E, and we can
refer both of them simply as “energy’ (Finkelstein and Ptitsyn
2002). Likewise, there is no difference between Helmholtz free
energy (F = E − TS) and Gibb’s free energy (G = H − TS),
since we consider that H is equivalent to E. As a result, we
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Table 7.3. The Characteristic of Each Type of Inhibition and Their Effect on the Kinetic Parameters Km and Vmax
Inhibitor Type Binding Site on Enzyme Kinetic Effect
Competitive Inhibitor The inhibitor specifically binds at the
enzyme’s catalytic site, where it competes
with substrate for binding:
 E + P ES E 
+S
-S →
I
–I
EI 
Km is increased; Vmax is unchanged.
LB equation:
1
v
= Km
Vmax
(
1 + [I ]
Ki
)
1
[S] +
1
Vmax
Non-competitive Inhibitor The inhibitor binds to E or to the ES
complex (may form an ESI complex) at a
site other than the catalytic. Substrate
binding is unchanged, whereas ESI
complex cannot form products.
 E + P ES E 
+S
-S →
 E + P ES 
+S
-S
I
–I
I
–I
EI 
Km is unchanged; Vmax is decreased proportionately
to inhibitor concentration.
LB equation:
1
v
= Km
Vmax
·
(
1 + [I ]
Ki
)
· 1[S] +
1
Vmax
(
1 + [I ]
Ki
)
Uncompetitive Inhibitor Binds only to ES complexes at a site other
than the catalytic site. Substrate binding
alters enzyme structure, making
inhibitor-binding site available:
EIS
 E + P ES E 
+S
-S →
I
–I
Km and Vmax are decreased.
LB equation:
1
v
= Km
Vmax
· 1[S] +
1
Vmax
(
1 + [I ]
Ki
)
can refer both F and G as ‘free energy’ (Finkelstein and Ptitsyn
2002). Eventually, when we study the thermodynamic behaviour
of an enzyme, regarding its structural stability or its functionality,
we have to do with Gibb’s free energy (G), entropy (S) and
enthalpy (H).
As far as experimental procedures are concerned, someone
can use two equations in order to measure the thermodynamic
parameters, applying temperature differentiation experimental
protocols (Kotzia and Labrou 2005). These equations are the
Arrhenius (Equation 4) and the Eyring equations, which basi-
cally describe the temperature dependence of reaction state. So,
considering an enzymic reaction as a chemical reaction, which
is characterised by a transition state, we can efficiently use the
Eyring’s equation. This equation is based on transition state
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model, whose principles are (i) there is a thermodynamic equi-
librium between the transition state and the state of reactants at
the top of the energy barrier and (ii) the rate of chemical reac-
tion is proportional to the concentration of the particles in the
high-energy transition state.
Combining basic kinetic expressions, which describe a simple
chemical reaction:
A + B C
Scheme 7.6.
and thermodynamic equations, such as (Finkelstein and Ptitsyn
2002)
G = −RT ln k
G = H − T S
Eyring’s equation is formed:
k = kβT
h
e−(
G
RT
) = kβT
h
e−(
H
RT
− S
R
)
where k is the reaction velocity, R is the universal gas
constant (8.3145 J · mol−1 K), kB the Boltzmann’s constant
(1.381 · 10−23 J · K−1), h is the Plank constant (6.626 · 10−34 J · s)
and T is the absolute temperature in degrees Kelvin (K). If
we compare Eyring’s equation and Arrhenius equation (Laidler
1984), we can realise that E and H are parallel quantities, as we
concluded above. Eyring’s equation is an appropriate and useful
tool, which allows us to simplify the complicated meaning of
thermodynamics and, simultaneously, to interpret experimental
data to physical meanings.
Enzyme Dynamics During Catalysis
Multiple conformational changes and intramolecular motions
appear to be a general feature of enzymes (Agarwal et al. 2002).
The structures of proteins and other biomolecules are largely
maintained by non-covalent forces and are therefore subject to
thermal fluctuations ranging from local atomic displacements to
complete unfolding. These changes are intimately connected to
enzymatic catalysis and are believed to fulfil a number of roles in
catalysis: enhanced binding of substrate, correct orientation of
catalytic groups, removal of water from the active site and trap-
ping of intermediates. Enzyme conformational changes may be
classified into four types (Gutteridge and Thornton 2004): (i)
domain motion, where two rigid domains, joined by a flexi-
ble hinge, move relative to each other; (ii) loop motion, where
flexible surface loops (2–10 residues) adopt different conforma-
tions; (iii) side chain rotation, which alters the position of the
functional atoms of the side chain and (iv) secondary structure
changes.
Intramolecular motions in biomolecules are usually very fast
(picosecond–nanosecond) local fluctuations. The flexibility as-
sociated with such motions provides entropic stabilisation of
conformational states (Agarwal et al. 2002). In addition, there are
also slower- (microsecond–millisecond) and larger-scale, ther-
mally activated, transitions. Large-scale conformational changes
are usually key events in enzyme regulation.
ENZYME PRODUCTION
In the past, enzymes were isolated primarily from natural
sources, and thus a relatively limited number of enzymes were
available to the industry (Aehle 2007). For example, of the hun-
dred or so enzymes being used industrially, over one half are
from fungi and yeast and over a third are from bacteria, with the
remainder divided between animal (8%) and plant (4%) sources
(Panke and Wubbolts 2002, van Beilen and Li 2002, Bornscheuer
2005). Today, with the recent advances of molecular biology and
genetic engineering, several expression systems were developed
and exploited and used for the commercial production of several
therapeutic (Mcgrath 2005), analytical or industrial enzymes
(van Beilen and Li 2002, Kirk et al. 2002, Otero and Nielsen
2010). These systems have not only improved the efficiency,
availability and cost with which enzymes can be produced, but
they have also improved their quality (Labrou and Rigden 2001,
Andreadeli et al. 2008, Kapoli et al. 2008, Kotzia and Labrou
2009, Labrou 2010).
Enzyme Heterologous Expression
There are two basic steps involved in the assembly of every
heterologous expression system:
1. The introduction of the DNA, encoding the gene of inter-
est, into the host cells, which requires: (i) the identification
and isolation of the gene of the protein we wish to express,
(ii) insertion of the gene into a suitable expression vector
and (iii) introduction of the expression vector into the se-
lected cell system that will accommodate the heterologous
protein.
2. The optimisation of protein expression by taking into
account the effect of various factors such as growing
medium, temperature, and induction period.
A variety of vectors able to carry the DNA into the host
cells are available, ranging from plasmids, cosmids, phagemids,
viruses as well as artificial chromosomes of bacterial, yeast or
human origin (BAC, YAC or HAC, respectively; Grimes and
Monaco 2005, Monaco and Moralli 2006, Takahashi and Ueda
2010). The vectors are either integrated into the host chromoso-
mal DNA or remain in an episomal form. In general, expression
vectors have the following characteristics (Fig. 7.11):
1. Polylinker: it contains multiple restriction sites that facili-
tate the insertion of the desired gene into the vector.
2. Selection marker: encodes for a selectable marker, allow-
ing the vector to be maintained within the host cell under
conditions of selective pressure (i.e. antibiotic).
3. Ori: a sequence that allows for the autonomous replication
of the vector within the cells.
4. Promoter: inducible or constitutive, that regulates RNA
transcription of the gene of interest.
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Figure 7.11. Generalised heterologous gene expression vector.
Polylinker sequence (multiple cloning site (MCS)), promoter
(Peuk/pro), terminator (Teuk/pro), selectable marker (prokaryotic and/or
eukaryotic – Meuk/pro), and origin of replication (eukaryotic and/or
prokaryotic – Orieuk/pro).
5. Terminator: a strong terminator sequence that ensures that
the RNA polymerase disengages and does not continue to
transcribe other genes located downstream.
Vectors are usually designed with mixed characteristics for ex-
pression in both prokaryotic and eukaryotic host cells (Brondyk
2009, Demain and Vaishnav 2009). Artificial chromosomes are
designed for cloning of very large segments of DNA (100 kb),
usually for mapping purposes, and contain host-specific telom-
eric and centromeric sequences. These sequences permit the
proper distribution of the vectors to the daughter cells during
cell division and increase chromosome stability (Fig. 7.12).
The Choice of Expression System
There are two main categories of expression systems: eukary-
otic and prokaryotic (Demain and Vaishnav 2009). The choice
of a suitable expression system involves the consideration of
several important factors, such as protein yield, proper folding,
post-translational modifications (e.g. phosphorylation, glycosy-
lation), industrial applications of the expressed protein, as well
as economic factors. For these reasons, there is no universally
applied expression system. A comparison of the most commonly
used expression systems is shown in Table 7.4.
Bacterial Cells
Expression of heterologous proteins in bacteria remains the most
extensively used approach for the production of heterologous
proteins (Zerbs et al. 2009), such as cytokines (Tang et al.
2006, Rabhi-Essafi et al. 2007), membrane proteins (Butzin
Figure 7.12. Artificial chromosome cloning system. Initially, the
circular vector is digested with restriction endonucleases (RE) for
linearisation and then ligated with size-fractionated DNA (≈100 kb).
The vector contains centromeric and telomeric sequences, which
assure chromosome-like propagation within the cell, as well as
selection marker sequences for stable maintenance. Origin of
replication (eukaryotic or prokaryotic – Orieuk/pro), selectable marker
(eukaryotic or prokaryotic – Meuk/pro), centromeric sequence (C),
and telomeric sequence (T).
et al. 2009, Zoonens and Miroux 2010), enzymes (Melissis et al.
2006, Kotzia and Labrou 2007, Melissis et al. 2007, Andread-
eli et al. 2008, Wu et al. 2009, Okino et al. 2010), antibodies
(Kwong and Rader 2009, Xiong et al. 2009) and antigens (vi-
ral or non-viral; Donayre-Torres et al. 2009, Liu et al. 2009a,
Vahedi et al. 2009, Ebrahimi et al. 2010) at both laboratory and
industrial scale (Koehn and Hunt 2009, Sahdev et al. 2008, Peti
and Page 2007, Jana and Deb 2005). Bacteria can be grown
inexpensively and genetically manipulated very easily. They
can reach very high densities rapidly and express high levels
of recombinant proteins, reaching up to 50% of the total pro-
tein. However, in many cases, high-level expression correlates
with poor quality. Often, the expressed protein is accumulated
in the form of insoluble inclusion bodies (misfolded protein
aggregate) and additional, sometimes labour-intensive, genetic
manipulation or re-solubilisation/refolding steps are required
(Burgess 2009). Bacterial cells do not possess the eukaryotes’
extensive post-translational modification system (such as N- or
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Table 7.4. Comparison of the Main Expression Systems
Mammalian Transgenic Transgenic
Bacteria Yeast Fungi Insect Cells Cells Plants Animals
Developing time Short Short Short Intermediate Intermediate Intermediate Long
Costs for downstream
processing
+++ ++ ++ ++ ++ ++ ++
Levels of expression High Intermediate Intermediate Intermediate Low Low Low
Recombinant protein stability +/− +/− +/− +/− +/− +++ +/−
Production volume Limited Limited Limited Limited Limited Unlimited Unlimited
Postranslational modifications
(disulphide bond
formation, glycosylation,
etc.)
No Yes Yes Yes Yes Yes Yes
‘Human-type’ glycosylation No No No No Yes No Yes
Folding capabilities − ++ +++ +++ +++ +++ +++
Contamination level
(pathogens, EPL, etc.)
++ − − − ++ − ++
O-glycosylation), a serious disadvantage, when post-
translational modifications are essential to the protein’s function
(Zhang et al. 2004). However, they are capable of a surpris-
ingly broad range of covalent modifications such as acetylation,
amidation and deamidation, methylation, myristylation, biotiny-
lation and phosphorylation.
Mammalian Cells
Mammalian cells are the ideal candidate for expression hosts
(Engelhardt et al. 2009, Hacker et al. 2009) when post-
translational modifications (N- and O-glycosylation, disulfide
bond formation) are a critical factor for the efficacy of the ex-
pressed protein (Baldi et al. 2007, Werner et al. 2007, Durocher
and Butler 2009, Geisse and Fux 2009, Hacker et al. 2009).
Despite substantial limitations, such as high cost, low yield, in-
stability of expression and time-consuming, a significant number
of proteins (e.g. cytokines; Fox et al. 2004, Sunley et al. 2008,
Suen et al. 2010), antibodies (Kim et al. 2008, Chusainow et al.
2009), enzymes (Zhuge et al. 2004), viral antigens (Holzer et al.
2003), blood factors and related proteins (Halabian et al. 2009,
Su et al. 2010) are produced in this system because it offers
very high product fidelity. However, oligosaccharide process-
ing is species- and cell type-dependent among mammalian cells
and differences in the glycosylation pattern have been reported
in rodent cell lines and human tissues. The expressed proteins
are usually recovered in a bioactive, properly folded form and
secreted into the cell culture fluids.
Yeast
Yeast is a widely used expression system with many commercial,
medical and basic research applications. The fact that the yeast is
the most intensively studied eukaryote at the genetic/molecular
level makes it an extremely advantageous expression system
(Idiris et al. 2010). Being unicellular organism, it retains the
advantages of bacteria (low cultivation cost, high doubling rate,
ease of genetic manipulation, ability to produce heterologous
proteins in large-scale quantities) combined with the advantages
of higher eukaryotic systems (post-translational modifications).
The vast majority of yeast expression work has focused on
the well-characterised baker’s yeast Saccharomyces cerevisiae
(Holz et al. 2003, Terpitz et al. 2008, Joubert et al. 2010), but
a growing number of non-Saccharomyces yeasts are becoming
available as hosts for recombinant polypeptide production, such
as Hansenula polymorpha, Candida boidinii, Kluyveromyces
lactis, Pichia pastoris (Cregg et al. 2000, Jahic et al. 2006, van
Ooyen et al. 2006, Yurimoto and Sakai 2009), Schizosaccha-
romyces pombe (Alberti et al. 2007, Ahn et al. 2009, Takegawa
et al. 2009), Schwanniomyces occidentalis and Yarrowia lipoly-
tica (Madzak et al. 2004, 2005, Bankar et al. 2009). As in bac-
teria, expression in yeast relies on episomal or integrated multi-
copy plasmids with tightly regulated gene expression. Despite
these advantages, expressed proteins are not always recovered
in soluble form and may have to be purified from inclusion bod-
ies. Post-translational modifications in yeast differ greatly from
mammalian cells (Jacobs and Callewaert 2009, Hamilton and
Gerngross 2007). This has sometimes proven to be a hindrance
when high fidelity of complex carbohydrate modifications found
in eukaryotic proteins appears to be important in many medical
applications. Yeast cells do not add complex oligosaccharides
and are limited to the high-mannose-type carbohydrates. These
higher order oligosaccharides are possibly immunogenic and
could potentially interfere with the biological activity of the
protein.
Filamentous Fungi
Filamentous fungi have been extensively used for studies of
eukaryotic gene organisation, regulation and cellular differen-
tiation. Additionally, fungi belonging to the genus Aspergillus
and Penicillium are of significant industrial importance because
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of their applications in food fermentation and their ability to
secrete a broad range of biopolymer degrading enzymes and to
produce primary (organic acids) and secondary metabolites (an-
tibiotics, vitamins). The extensive genetic knowledge as well as
the already well-developed fermentation technology has allowed
for the development of heterologous protein expression systems
(Nevalainen et al. 2005, Wang et al. 2005) expressing fungal
(e.g. glucoamylase (Verdoes et al. 1993), propyl aminopepti-
dase (Matsushita-Morita et al. 2009)) or mammalian (e.g. hu-
man interleukin-6 (Contreras et al. 1991), antitrypsin (Chill et al.
2009), lactoferrin (Ward et al. 1995), bovine chymosin (Ward
et al. 1990, Cardoza et al. 2003)) proteins of industrial and clin-
ical interest using filamentous fungi as hosts. However, the ex-
pression levels of mammalian proteins expressed in Aspergillus
and Trichoderma species are low compared to homologous pro-
teins. Significant advances in heterologous protein expression
have dramatically improved the expression efficiency by fus-
ing the heterologous gene to the 3′-end of a highly expressed
homologous gene (mainly glucoamylase). Even so, limitations
in protein folding, post-translational modifications, transloca-
tion and secretion as well as secretion of extracellular proteases
could pose a significant hindrance for the production of bioactive
proteins (Gouka et al. 1997, Nevalainen et al. 2005, Lubertozzi
and Keasling 2009).
Insect Cells
Recombinant baculoviruses are widely used as a vector for the
expression of recombinant proteins in insect cells (Hitchman
et al. 2009, Jarvis 2009, Trometer and Falson 2010), such as
enzymes (Zhao et al. 2010), immunoglobulins (Iizuka et al.
2009), viral antigens (Takahashi et al. 2010) and transcription
factors (Fabian et al. 1998). The recombinant genes are usually
expressed under the control of the polyhedrin or p10 promoter
of the Autographa californica nuclear polyhedrosis virus (Ac-
NPV) in cultured insect cells of Spodoptera frugiperda (Sf9
cells) or in insect larvae of Lepidopteran species infected with
the recombinant baculovirus containing the gene of interest. The
polyhedron and p10 genes possess very strong promoters and
are highly transcribed during the late stages of the viral cycle.
Usually, the recombinant proteins are recovered from the in-
fected insect cells in soluble form and targeted in the proper
cellular environment (membrane, nucleus and cytoplasm). In-
sect cells have many post-translational modification, transport
and processing mechanisms found in higher eukaryotic cells
(Durocher and Butler 2009), although their glycosylation effi-
ciency is limited and they are not able to process complex-type
oligosaccharides containing fucose, galactose and sialic acid.
Dictyostelium discoideum
Recently, the cellular slime mould Dictyostelium discoideum, a
well-studied single-celled organism, has emerged as a promis-
ing eukaryotic alternative system (Arya et al. 2008b) for the
expression of recombinant proteins (e.g. human antithrombin
III; Dingermann et al. 1991, Tiltscher and Storr 1993, Dittrich
et al. 1994) and enzymes (e.g. phosphodiesterase; Arya et al.
2008a). Its advantage over other expression systems lies in its
extensive post-translational modification system (glycosylation,
phosphorylation, acylation), which resembles that of higher eu-
karyotes (Jung and Williams 1997, Jung et al. 1997, Slade et al.
1997). It is a simple organism with a haploid genome of 5 ×
107 bp and a life cycle that alternates between single-celled and
multicellular stages. Recombinant proteins are expressed from
extrachromosomal plasmids (Dictyostelium discoideum is one
of a few eukaryotes that have circular nuclear plasmids) rather
than being integrated in the genome (Ahern et al. 1988). The nu-
clear plasmids can be easily genetically manipulated and isolated
in a one-step procedure, as in bacteria. This system is ideally
suited for the expression of complex glycoproteins and although
it retains many of the advantages of the bacterial (low cultivation
cost) and mammalian systems (establishment of stable cell lines,
glycosylation), the development of this system at an industrial
scale is hampered by the relatively low productivity, compared
to bacterial systems.
Trypanosomatid Protozoa
A newly developed eukaryotic expression system is based on the
protozoan lizard parasites of the Leishmania and Trypanosoma
species (Basile and Peticca 2009). Its gene and protein regula-
tion and editing mechanisms are remarkably similar to those of
higher eukaryotes and include the capability of ‘mammalian-
like’ glycosylation. It has a very rapid doubling time and can be
grown to high densities in relatively inexpensive medium. The
recombinant gene is integrated into the small ribosomal subunit
rRNA gene and can be expressed to high levels. Increased ex-
pression levels and additional promoter control can be achieved
in T7 polymerase-expressing strains. Being a lizard parasite, it is
not pathogenic to humans, which makes this system invaluable
and highly versatile. Proteins and enzymes of significant inter-
est, such as human tissue plasminogen activator (Soleimani et al.
2007), EPO (Breitling et al. 2002), IFNγ (Tobin et al. 1993) and
IL-2 (La Flamme 1995), have been successfully expressed in
this system.
Transgenic Plants
The current protein therapeutics market is clearly an area of
enormous interest from a medical and economic point of view.
Recent advances in human genomics and biotechnology have
made it possible to identify a plethora of potentially impor-
tant drugs or drug targets. Transgenic technology has provided
an alternative, more cost-effective bioproduction system than
the previously used (E. coli, yeast, mammalian cells; Larrick
and Thomas 2001, Demain and Vaishnav 2009). The accumu-
lated knowledge on plant genetic manipulation has been re-
cently applied to the development of plant bioproduction sys-
tems (Twyman et al. 2005, Boehm 2007, Lienard et al. 2007,
Faye and Champey 2008, Sourrouille et al. 2009). Expression in
plants could be either constitutive or transient and directed to a
specific tissue of the plant (depending on the type of promoter
used). Expression of heterologous proteins in plants offers sig-
nificant advantages, such as low production cost, high biomass
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production, unlimited supply and ease of expandability. Plants
also have high-fidelity expression, folding and post-translational
modification mechanisms, which could produce human proteins
of substantial structural and functional equivalency compared
to proteins from mammalian expression systems (Gomord and
Faye 2004, Joshi and Lopez 2005). Additionally, plant-made hu-
man proteins of clinical interest (Schillberg et al. 2005, Twyman
et al. 2005, Vitale and Pedrazzini 2005, Tiwari et al. 2009), such
as antibodies (Hassan et al. 2008, Ko et al. 2009, De Muynck
et al. 2010, Lai et al. 2010), vaccines (Hooper 2009, Alvarez
and Cardineau 2010), cytokines (Elias-Lopez et al. 2008) and
enzymes (Kermode et al. 2007, Stein et al. 2009), are free of po-
tentially hazardous human diseases, viruses or bacterial toxins.
However, there is considerable concern regarding the potential
hazards of contamination of the natural gene pool by the trans-
genes and possible additional safety precautions will raise the
production cost.
Transgenic Animals
Besides plants, transgenic technology has also been applied to
many different species of animals (mice, cows, rabbits, sheep,
goats and pigs; Niemann and Kues 2007, Houdebine 2009).
The DNA containing the gene of interest is microinjected into
the pronucleus of a single-cell fertilised zygote and integrated
into the genome of the recipient; therefore, it can be faithfully
passed on from generation to generation. The gene of interest
is coupled with a signal targeting protein expression towards
specific tissues, mainly the mammary gland, and the protein
can therefore be harvested and purified from milk. The proteins
produced by transgenic animals are almost identical to human
proteins, greatly expanding the applications of transgenic ani-
mals in medicine and biotechnology. Several human protein of
pharmaceutical value have been produced in transgenic animals,
such as haemoglobin (Swanson 1992, Logan and Martin 1994),
lactoferrin (Han et al. 2008, Yang et al. 2008), antithrombin III
(Yang et al. 2009), protein C (Velander 1992) and fibrinogen
(Prunkard 1996), and there is enormous interest for the genera-
tion of transgenic tissues suitable for transplantation in humans
(only recently overshadowed by primary blastocyte technology
(Klimanskaya et al. 2008)). Despite the initial technological ex-
pertise required to produce a transgenic animal, the subsequent
operational costs are low and subsequent inbreeding ensures that
the ability to produce the transgenic protein will be passed on
to its offspring. However, certain safety issues have arisen con-
cerning the potential contamination of transgenically produced
proteins by animal viruses or prions, which could possibly be
passed on to the human population. Extensive testing required
by the FDA substantially raises downstream costs.
Enzyme Purification
Once a suitable enzyme source has been identified, it becomes
necessary to design an appropriate purification procedure to iso-
late the desired protein. The extent of purification required for
an enzyme depends on several factors, the most important of
which being the degree of enzyme purity required as well as
Table 7.5. Protein Properties Used During Purification
Protein Property Technique
Solubility Precipitation
Size Gel filtration
Charge Ion exchange
Hydrophobicity Hydrophobic interaction chromatography
Biorecognition Affinity chromatography
the starting material, for example the quantity of the desired
enzyme present in the initial preparation (Lesley 2001, Labrou
and Clonis 2002). For example, industrial enzymes are usually
produced as relatively crude preparations. Enzymes used for
therapeutic or diagnostic purposes are generally subjected to the
most stringent purification procedures, as the presence of com-
pounds other than the intended product may have an adverse
clinical impact (Berthold and Walter 1994).
Purification of an enzyme usually occurs by a series of inde-
pendent steps in which the various physicochemical properties
of the enzyme of interest are utilised to separate it progressively
from other unwanted constituents (Labrou and Clonis 2002,
Labrou et al. 2004b). The characteristics of proteins that are
utilised in purification include solubility, ionic charge, molec-
ular size, adsorption properties and binding affinity to other
biological molecules. Several methods that exploit differences
in these properties are listed in Table 7.5.
Precipitation methods (usually employing (NH4)2SO4,
polyethyleneglycol or organic solvents) are not very efficient
method of purification (Labrou and Clonis 2002). They typ-
ically give only a few fold purification. However, with these
methods, the protein may be removed from the growth medium
or from cell debris where harmful proteases and other detri-
mental compounds may affect protein stability. On the other
hand, chromatography is a highly selective separation tech-
nique (Regnier 1987, Fausnaugh 1990). A wide range of chro-
matographic techniques has been used for enzyme purification:
size-exclusion chromatography, ion-exchange, hydroxyapatite,
hydrophobic interaction chromatography, reverse-phase chro-
matography and affinity chromatography (Labrou 2003). Of
these, ion-exchange and affinity chromatography are the most
common and probably the most important (Labrou and Clonis
1994).
Ion-Exchange Chromatography
Ion-exchange resins selectively bind proteins of opposite charge;
that is, a negatively charged resin will bind proteins with a net
positive charge and vice versa (Fig. 7.13). Charged groups are
classified according to type (cationic and anionic) and strength
(strong or weak); the charge characteristics of strong ion ex-
change media do not change with pH, whereas with weak ion-
exchange media they do. The most commonly used charged
groups include diethylaminoethyl, a weakly anionic exchanger;
carboxymethyl, a weakly cationic exchanger; quaternary am-
monium, a strongly anionic exchanger; and methyl sulfonate,
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Figure 7.13. (A) Schematic diagram of a chromatogram showing
the steps for a putative purification. (B) Schematic diagram
depicting the principle of ion-exchange chromatography.
a strongly cationic exchanger (Table 7.6; Levison 2003). The
matrix material for the column is usually formed from beads of
carbohydrate polymers, such as agarose, cellulose or dextrans
(Levison 2003).
The technique takes place in five steps (Labrou 2000;
Fig. 7.13): equilibration of the column to pH and ionic strength
conditions suitable for target protein binding; protein sample
application to the column and reversible adsorption through
counter-ion displacement; washing of the unbound contami-
nating proteins, enzymes, nucleic acids and other compounds;
introduction of elution conditions in order to displace bound
proteins; and regeneration and re-equilibration of the adsorbent
for subsequent purifications. Elution may be achieved either by
increasing the salt concentration or by changing the pH of the
irrigating buffer. Both methods are used in industry, but rais-
ing the salt concentration is by far the most common because it
is easier to control (Levison 2003). Most protein purifications
are done on anion exchange columns because most proteins are
negatively charged at physiological pH values (pH 6–8).
Affinity Chromatography
Affinity chromatography is potentially the most powerful and
selective method for protein purification (Fig. 7.14; Labrou
and Clonis 1994, Labrou 2003). According to the International
Union of Pure and Applied Chemistry, affinity chromatography
is defined as a liquid chromatographic technique that makes use
of a ‘biological interaction’ for the separation and analysis of
specific analytes within a sample. Examples of these interactions
include the binding of an enzyme with a substrate/inhibitor or
of an antibody with an antigen or in general the interaction of
a protein with a binding agent, known as the ‘affinity ligand’
(Fig. 7.14; Labrou 2002, 2003, Labrou et al. 2004b). The devel-
opment of an affinity chromatography-based purification step
involves the consideration of the following factors: (i) selection
of an appropriate ligand and (ii) immobilisation of the ligand
onto a suitable support matrix to make an affinity adsorbent.
The selection of the immobilised ligand for affinity chromatog-
raphy is the most challenging aspect of preparing an affinity
adsorbent. Certain factors need to be considered when selecting
a ligand (Labrou and Clonis 1995, 1996): (i) the specificity of
the ligand for the protein of interest, (ii) the reversibility of the
interaction with the protein, (iii) its stability against the biolog-
ical and chemical operation conditions and (iv) the affinity of
the ligand for the protein of interest. The binding site of a pro-
tein is often located deep within the molecule and adsorbents
prepared by coupling the ligands directly to the support exhibit
low binding capacities. This is due to steric interference between
the support matrix and the protein’s binding site. In these cir-
cumstances, a ‘spacer arm’ is inserted between the matrix and
ligand to facilitate effective binding (Fig. 7.14). A hexyl spacer
is usually inserted between ligand and support by substitution
of 1,6-diaminohexane (Lowe 2001).
The ideal matrix should be hydrophilic, chemically and bio-
logically stable and have sufficient modifiable groups to permit
an appropriate degree of substitution with the enzyme. Sepharose
is the most commonly used matrix for affinity chromatography
on the research scale. Sepharose is a commercially available
beaded polymer, which is highly hydrophilic and generally inert
to microbiological attack (Labrou and Clonis 2002). Chemically,
it is an agarose (poly-{β-1,3-d-galactose-α-1,4-(3,6-anhydro)-
l-galactose}) derivative.
The selection of conditions for an optimum affinity chromato-
graphic purification involves the study of the following factors:
(1) choice of adsorption conditions (e.g. buffer composition,
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Table 7.6. Functional Groups Used on Ion Exchangers
Functional Group
Anion exchangers
Diethylaminoethyl (DEAE) –O–CH2–CH2–N+H(CH2CH3)2
Quaternary aminoethyl (QAE) –O–CH2–CH2–N+(C2H5)2–CH2–CHOH–CH3
Quaternary ammonium (Q) –O–CH2–CHOH–CH2O–CH2–CHOH–CH2N+(CH3)2
Cation exchangers
Carboxymethyl (CM) –O–CH2–COO−
Sulphopropyl (SP) –O–CH2–CHOH–CH2–O–CH2–CH2–CH2SO3−
pH, ionic strength) to maximise the conditions required for the
formation of strong complex between the ligand and the pro-
tein to be purified, (2) choice of washing conditions to desorb
non-specifically bound proteins and (3) choice of elution con-
ditions to maximise purification (Labrou and Clonis 1995). The
elution conditions of the bound macromolecule should be both
Figure 7.14. Schematic diagram depicting the principle of affinity
chromatography.
tolerated by the affinity adsorbent and effective in desorbing
the biomolecule in good yield and in the native state. Elution
of bound proteins is performed in a non-specific or biospecific
manner. Non-specific elution usually involves (1) changing the
ionic strength (usually by increasing the buffer’s molarity or
including salt, e.g. KCl or NaCl) and the pH (adsorption gen-
erally weakens with increasing pH), (2) altering the polarity of
the irrigating buffer by employing, for example ethylene glycol
or other organic solvents, if the hydrophobic contribution in the
protein-ligand complex is large. Biospecific elution is achieved
by inclusion in the equilibration buffer of a suitable ligand, which
usually competes with the immobilised ligand for the same bind-
ing site on the enzyme/protein (Labrou 2000). Any competing
ligand may be used. For example, substrates, products, cofac-
tors, inhibitors or allosteric effectors are all potential candidates
as long as they have higher affinity for the macromolecule than
the immobilised ligand.
Dye-ligand affinity chromatography represents a powerful
affinity-based technique for enzyme and protein purification
(Clonis et al. 2000, Labrou 2002, Labrou et al. 2004b). The tech-
nique has gained broad popularity due to its simplicity and wide
applicability to purify a variety of proteins. The employed dyes
as affinity ligands are commercial textile chlorotriazine polysul-
fonated aromatic molecules, which are usually termed as triazine
dyes (Fig. 7.15). Such dye-ligands have found wide applications
over the past 20 years as general affinity ligands in the research
market to purify enzymes, such as oxidoreductases, decarboxy-
lases, glycolytic enzymes, nucleases, hydrolases, lyases, syn-
thetases and transferases (Scopes 1987). Anthraquinone triazine
dyes are probably the most widely used dye-ligands in enzyme
and protein purification. Especially the triazine dye Cibacron
Blue F3GA (Fig. 7.18) has been widely exploited as an affinity
chromatographic tool to separate and purify a variety of pro-
teins (Scopes 1987). With the aim of increasing the specificity
of dye-ligands, the biomimetic dye-ligand concept was intro-
duced. According to this concept, new dyes that mimic natural
ligands of the targeted proteins are designed by substituting the
terminal 2-aminobenzene sulfonate moiety of the dye Cibacron
Blue 3GA (CB3GA) for (η´ with) a substrate-mimetic moiety
(Clonis et al. 2000, Labrou 2002, 2003, Labrou et al. 2004b).
These biomimetic dyes exhibit increased purification ability and
specificity and provide useful tools for designing simple and
effective purification protocols.
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Figure 7.15. Structure of several representative triazine dyes: (A) Cibacron Blue 3GA, (B) Procion Red HE-3B and (C) Procion Rubine MX-B.
The rapid development of recombinant DNA technology since
the early 1980s has changed the emphasis of a classical enzyme
purification work. For example, epitope tagging is a recombinant
DNA method for inserting a specific protein sequence (affinity
tag) into the protein of interest (Terpe 2003). This allows the
expressed tagged protein to be purified by affinity interactions
with a ligand that selectively binds to the affinity tag. Examples
of affinity tags and their respective ligands used for protein and
enzyme purification are shown in Table 7.7.
ENZYME ENGINEERING
Another extremely promising area of enzyme technology is en-
zyme engineering. New enzyme structures may be designed and
produced in order to improve existing ones or create new ac-
tivities. Over the past two decades, with the advent of protein
engineering, molecular biotechnology has permitted not only
the improvement of the properties of these isolated proteins, but
also the construction of ‘altered versions’ of these ‘naturally
occurring’ proteins with novel or ‘tailor-made’ properties (Ryu
Table 7.7. Adsorbents and Elution Conditions of Affinity Tags
Affinity Tag Matrix Elution Condition
Poly-His Ni2+-NTA Imidazole 20–250 mM or low pH
FLAG Anti-FLAG monoclonal antibody pH 3.0 or 2–5 mM EDTA
Strep-tag II Strep-Tactin (modified streptavidin) 2.5 mM desthiobiotin
c-myc Monoclonal antibody Low pH
S S-fragment of RNaseA 3 M guanidine thiocyanate, 0.2 M citrate pH 2, 3 M
magnesium chloride
Calmodulin-binding peptide Calmodulin EGTA or EGTA with 1 M NaCl
Cellulose-binding domain Cellulose Guanidine HCl or urea > 4 M
Glutathione S-transferase Glutathione 5–10 mM reduced glutathione
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Figure 7.16. Comparison of rational design and directed evolution.
and Nam 2000, Gerlt and Babbitt 2009, Tracewell and Arnold
2009).
Tailor-Made Enzymes by Protein Engineering
There are two main intervention approaches for the construction
of tailor-made enzymes: rational design and directed evolution
(Chen 2001, Schmidt et al. 2009; Fig. 7.16).
Rational design takes advantage of knowledge of the
three-dimensional structure of the enzyme, as well as struc-
ture/function and sequence information to predict, in a ‘ratio-
nal/logical’ way, sites on the enzyme that when altered would
endow the enzyme with the desired properties (Craik et al.
1985, Wells et al. 1987, Carter et al. 1989, Scrutton et al. 1990,
Cedrone et al. 2000). Once the crucial amino acids are identified,
site-directed mutagenesis is applied and the expressed mutants
are screened for the desired properties. It is clear that protein en-
gineering by rational design requires prior knowledge of the ‘hot
spots’ on the enzyme. Directed evolution (or molecular evolu-
tion) does not require such prior sequence or three-dimensional
structure knowledge, as it usually employs random-mutagenesis
protocols to engineer enzymes that are subsequently screened
for the desired properties (Tao and Cornish 2002, Dalby 2003,
Jaeger and Eggert 2004, Jestin and Kaminski 2004, Williams
et al. 2004). However, both approaches require efficient expres-
sion as well as sensitive detection systems for the protein of
interest (Kotzia et al. 2006). During the selection process, the
mutations that have a positive effect are selected and identified.
Usually, repeated rounds of mutagenesis are applied until en-
zymes with the desired properties are constructed. For example,
it took four rounds of random mutagenesis and DNA shuffling of
Drosophila melanogaster 2′-deoxynucleoside kinase, followed
by FACS analysis, in order to yield an orthogonal ddT kinase
with a 6-fold higher activity for the nucleoside analogue and a
20-fold kcat/Km preference for ddT over thymidine, an overall
10,000-fold change in substrate specificity (Liu et al. 2009b).
Usually, a combination of both methods is employed by the
construction of combinatorial libraries of variants, using ran-
dom mutagenesis on selected (by rational design) areas of the
parental ‘wild-type’ protein (typically, binding surfaces or spe-
cific amino acids; Altamirano et al. 2000, Arnold 2001, Saven
2002, Johannes and Zhao 2006). For example, Park et al. ratio-
nally manipulated several active site loops in the ab/ba metal-
lohydrolase scaffold of glyoxalase II through amino acid inser-
tion, deletion, and substitution, and then used directed evolution
to introduce random point-mutations to fine-tune the enzyme
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activity (Park et al. 2006). The resulting enzyme completely lost
its original activity and instead showed β-lactamase activity.
The industrial applications of enzymes as biocatalysts are
numerous. Recent advances in genetic engineering have made
possible the construction of enzymes with enhanced or altered
properties (change of enzyme/cofactor specificity and enantios-
electivity, altered thermostability, increased activity) to satisfy
the ever-increasing needs of the industry for more efficient cata-
lysts (Bornscheuer and Pohl 2001, Zaks 2001, Jaeger and Eggert
2004, Chaput et al. 2008, Zeng et al. 2009).
Rational Enzyme Design
The rational protein design approach is mainly used for the
identification and evaluation of functionally important residues
or sites in proteins. Although the protein sequence contains all
the information required for protein folding and functions, to-
day’s state of technology does not allow for efficient protein
design by simple knowledge of the amino acid sequence alone.
For example, there are 10325 ways of rearranging amino acids
in a 250-amino-acid-long protein, and prediction of the number
of changes required to achieve a desired effect is an obstacle
that initially appears impossible. For this reason, a successful
rational design cycle requires substantial planning and could be
repeated several times before the desired result is achieved. A
rational protein design cycle requires the following:
1. Knowledge of the amino acid sequence of the enzyme of
interest and availability of an expression system that al-
lows for the production of active enzyme. Isolation and
characterisation (annotation) of cDNAs encoding pro-
teins with novel or pre-observed properties has been sig-
nificantly facilitated by advances in genomics (Schena
et al. 1995, Zweiger and Scott 1997, Schena et al. 1998,
Carbone 2009) and proteomics (Anderson and Anderson
1998, Anderson et al. 2000, Steiner and Anderson 2000,
Xie et al. 2009) and is increasing rapidly. These cDNA se-
quences are stored in gene (NCBI) and protein databanks
(UniProtKB/Swiss-Prot; Release 57.12 of 15 Dec 09 of
UniProtKB/Swiss-Prot contains 513,77 protein sequence
entries; Apweiler et al. 2004, The UniProt Consortium
2008). However, before the protein design cycle begins, a
protein expression system has to be established. Introduc-
tion of the cDNA encoding the protein of interest into a
suitable expression vector/host cell system is nowadays a
standard procedure (see above).
2. Structure/function analysis of the initial protein sequence
and determination of the required amino acids changes.
As mentioned before, the enzyme engineering process
could be repeated several times until the desired result
is obtained. Therefore, each cycle ends where the next
begins. Although, we cannot accurately predict the con-
formation of a given protein by knowledge of its amino
acid sequence, the amino acid sequence can provide sig-
nificant information. Initial screening should therefore
involve sequence comparison analysis of the original pro-
tein sequence to other sequence homologous proteins with
potentially similar functions by utilising current bioinfor-
matics tools (Andrade and Sander 1997, Fenyo and Beavis
2002, Nam et al. 2009, Yen et al. 2009, Zhang et al. 2009a,
2009b). Areas of conserved or non-conserved amino acids
residues can be located within the protein and could pos-
sibly provide valuable information, concerning the iden-
tification of binding and catalytic residues. Additionally,
such methods could also reveal information pertinent to
the three-dimensional structure of the protein.
3. Availability of functional assays for identification of
changes in the properties of the protein. This is probably
the most basic requirement for efficient rational protein de-
sign. The expressed protein has to be produced in a bioac-
tive form and characterised for size, function and stability
in order to build a baseline comparison platform for the en-
suing protein mutants. The functional assays should have
the required sensitivity and accuracy to detect the desired
changes in the protein’s properties.
4. Availability of the three-dimensional structure of the pro-
tein or capability of producing a reasonably accurate three-
dimensional model by computer modelling techniques.
The structures of thousands of proteins have been solved
by various crystallographic techniques (X-ray diffraction,
NMR spectroscopy) and are available in protein struc-
ture databanks. Current bioinformatics tools and elabo-
rate molecular modeling software (Wilkins et al. 1999,
Gasteiger et al. 2003, Guex et al. 2009) permit the accurate
depiction of these structures and allow the manipulation
of the aminoacid sequence. For example, they are able to
predict, with significant accuracy, the consequences of a
single aminoacid substitution on the conformation, elec-
trostatic or hydrophobic potential of the protein (Guex
and Peitsch 1997, Gasteiger et al. 2003, Schwede et al.
2003). Additionally, protein–ligand interactions can, in
some cases, be successfully simulated, which is especially
important in the identification of functionally important
residues in enzyme–cofactor/substrate interactions (Saxena
et al. 2009). Finally, in allosteric regulation, the induced
conformational changes are very difficult to predict. In
last few years, studies on the computational modelling of
allostery have also began (Kidd et al. 2009).
Where the three-dimensional structure of the protein of interest
is not available, computer modelling methods (homology mod-
elling, fold recognition using threading and ab initio prediction)
allow for the construction of putative models based on known
structures of homologous proteins (Schwede et al. 2003, Kopp
and Schwede 2004, Jaroszewski 2009, Qu et al. 2009). Addi-
tionally, comparison with proteins having homologous three-
dimensional structure or structural motifs could provide clues as
to the function of the protein and the location of functionally im-
portant sites. Even if the protein of interest shows no homology
to any other known protein, current amino acid sequence anal-
ysis software could provide putative tertiary structural models.
A generalised approach to predict protein structure is shown in
Figure 7.17.
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Figure 7.17. A generalised schematic for the prediction of protein three-dimensional structure.
5. Genetic manipulation of the wild-type nucleotide
sequence. A combination of previously published
experimental literature and sequence/structure analysis
information is usually necessary for the identification
of functionally important sites in the protein. Once an
adequate three-dimensional structural model of the protein
of interest has been constructed, manipulation of the gene
of interest is necessary for the construction of mutants.
Polymerase chain reaction (PCR) mutagenesis is the
basic tool for the genetic manipulation of the nucleotide
sequences. The genetically redesigned proteins are
engineered by the following:
a. Site-directed mutagenesis: alteration of specific amino
acid residues. There are a number of experimental
approaches designed for this purpose. The basic
principle involves the use of synthetic oligonucleotides
(oligonucleotide-directed mutagenesis) that are com-
plementary to the cloned gene of interest but contain
a single (or sometimes multiple) mismatched base(s)
(Balland et al. 1985, Garvey and Matthews 1990,
Wagner and Benkovic 1990). The cloned gene is
either carried by a single-stranded vector (M13
oligonucleotide-directed mutagenesis) or a plasmid
that is later denatured by alkali (plasmid DNA
oligonucleotide-directed mutagenesis) or heat
(PCR-amplified oligonucleotide-directed mutagenesis)
in order for the mismatched oligonucleotide to anneal.
The latter then serves as a primer for DNA synthesis
catalysed by externally added DNA polymerase for the
creation of a copy of the entire vector, carrying, how-
ever, a mutated base. PCR mutagenesis is the most fre-
quently used mutagenesis method (Fig. 7.18). For ex-
ample, substitution of specific amino acid positions by
site-directed mutagenesis (S67D/H68D) successfully
converted the coenzyme specificity of the short-chain
carbonyl reductase from NADP(H) to NAD(H) as well
as the product enantioselectivity without disturbing
enzyme stability (Zhang et al. 2009). In another exam-
ple, engineering of the maize GSTF1–1 by mutating
selected G-site residues resulted in substantial changes
in the pH-dependence of kinetic parameters of the
enzyme (Labrou et al. 2004a). Mutation of a key
residue in the H-site of the same enzyme (Ile118Phe)
led to a fourfold improved specificity of the en-
zyme towards the herbicide alachlor (Labrou et al.
2005).
So far, substitution of a specific amino acid by an-
other has been limited by the availability of only 20
naturally occurring amino acids. However, it is chemi-
cally possible to construct hundreds of designer-made
amino acids. Incorporation of these novel protein
building blocks could help shed new light into the
cellular and protein functions (Wang and Schultz 2002,
Chin et al. 2003, Deiters et al. 2003, Arnold 2009).
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Figure 7.18. PCR oligonucleotide-directed mutagenesis. Two sets of primers are used for the amplification of the double-stranded plasmid
DNA. The primers are positioned as shown and only one contains the desired base change. After the initial PCR step, the amplified PCR
products are mixed together, denatured and renatured to form, along with the original amplified linear DNA, nicked circular plasmids
containing the mutations. Upon transformation into E. coli, the nicked are repaired by host cell enzymes and the circular plasmids can be
maintained.
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b. Construction of deletion mutants: deletion of specified
areas within or at the 5′/3′ ends (truncation mutants) of
the gene.
c. Construction of insertion/fusion mutants: insertion of a
functionally/structurally important epitope or fusion to
another protein fragment.
There are numerous examples of fusion proteins de-
signed to facilitate protein expression and purification,
display of proteins on surfaces of cells or phages, cel-
lular localisation, metabolic engineering as well as
protein–protein interaction studies (Nixon et al. 1998).
d. Domain swapping: exchanging of protein domains
between homologous or heterologous proteins.
For example, exchange of a homologous region be-
tween Agrobacterium tumefaciens β-glucosidase (op-
timum at pH 7.2–7.4 and 60◦C) and Cellvibrio gilvus
β-glucosidase (optimum at pH 6.2–6.4 and 35◦C) re-
sulted in a hybrid enzyme with optimal activity at pH
6.6–7.0 and 45–50◦C (Singh et al. 1995). Also, domain
swapping was used to clarify the control of electron
transfer in nitric-oxide synthases (Nishida and Ortiz de
Montellano 2001). In another example, domain swap-
ping was observed in the structurally unrelated capsid
of a rice yellow mottle virus, a member of the plant
icosahedral virus group, where it was demonstrated to
increase stability of the viral particle (Qu et al. 2000).
Although site-directed mutagenesis is widely used, it is
not always feasible due to the limited knowledge of protein
structure–function relationship and the approximate nature of
computer-graphic modelling. In addition, rational design ap-
proaches can fail due to unexpected influences exerted by the
substitution of one or more amino acid residues (Cherry and
Fidantsef 2003, Johannes and Zhao 2006). Irrational approaches
can therefore be preferable alternatives to direct the evolution of
enzymes with highly specialised traits (Hibbert and Dalby 2005,
Chatterjee and Yuan 2006, Johannes and Zhao 2006).
Directed Enzyme Evolution
Directed evolution by DNA recombination can be described as
a mature technology for accelerating protein evolution. Evolu-
tion is a powerful algorithm with proven ability to alter enzyme
function and especially to ‘tune’ enzyme properties (Cherry and
Fidantsef 2003, Williams et al. 2004, Hibbert and Dalby 2005,
Roodveldt et al. 2005, Chatterjee and Yuan 2006). The methods
of directed evolution use the process of natural selection but in a
directed way (Altreuter and Clark 1999, Kaur and Sharma 2006,
Wong et al. 2006, Glasner et al. 2007, Gerlt and Babbitt 2009,
Turner 2009). The major step in a typical directed enzyme evolu-
tion experiment is first to make a set of mutants and then to find
the best variants through a high-throughput selection or screen-
ing procedure (Kotzia et al. 2006). The process can be iterative,
so that a ‘generation’ of molecules can be created in a few weeks
or even in a few days, with large numbers of progeny subjected
to selective pressures not encountered in nature (Arnold 2001,
Williams et al. 2004).
There are many methods to create combinatorial libraries,
using directed evolution (Labrou 2010). Some of these are ran-
dom mutagenesis using mainly error-prone PCR (Ke and Madi-
son 1997, Cirino et al. 2003), DNA shuffling (Stemmer 1994,
Crameri et al. 1998, Baik et al. 2003, Bessler et al. 2003, Dixon
et al. 2003, Wada et al. 2003), StEP (staggered extension process;
Zhao et al. 1998, Aguinaldo and Arnold 2003), RPR (random-
priming in vitro recombination; Shao et al. 1998, Aguinaldo
and Arnold 2003), incremental truncation for the creation of
hybrid enzymes (ITCHY; Lutz et al. 2001), RACHITT (ran-
dom chimeragenesis on transient templates; Coco et al. 2001,
Coco 2003), ISM (iterative saturation mutagenesis; Reetz 2007),
GSSM (gene site saturation mutagenesis; DeSantis et al. 2003,
Dumon et al. 2008), PDLGO (protein domain library generation
by overlap extension; Gratz and Jose 2008) and DuARCheM
(dual approach to random chemical mutagenesis; Mohan and
Banerjee 2008). The most frequently used methods for DNA
shuffling are shown in Figure 7.19.
Currently, directed evolution has gained considerable atten-
tion as a commercially important strategy for rapid design of
molecules with properties tailored for the biotechnological and
pharmaceutical market. Over the past four years, DNA family
shuffling has been successfully used to improve enzymes of in-
dustrial and therapeutic interest (Kurtzman et al. 2001, Chiang
2004, Dai and Copley 2004, Yuan et al. 2005). For example, by
applying the DNA family shuffling approach, the catalytic prop-
erties of cytochrome P450 enzymes were further extended in the
chimeric progeny to include a new range of blue colour forma-
tions. Therefore, it may be possible to direct the new enzymes
towards the production of new dyes (Rosic 2009).
IMMOBILISED ENZYMES
The term ‘immobilised enzymes’ describes enzymes physically
confined, localised in a certain region of space or attached on a
support matrix (Abdul 1993). The main advantages of enzyme
immobilisation are listed in Table 7.8.
There are at least four main areas in which immobilised en-
zymes may find applications, that is industrial, environmen-
tal, analytical and chemotherapeutic (Powell 1984, Liang et al.
2000). Environmental applications include waste water treat-
ment and the degradation of chemical pollutants of industrial
and agricultural origin (Dravis et al. 2001). Analytical appli-
cations include biosensors. Biosensors are analytical devices,
which have a biological recognition mechanism (most com-
monly enzyme) that transduce it into a signal, usually electrical,
and can be detected by using a suitable detector (Phadke 1992).
Immobilised enzymes, usually encapsulated, are also being used
for their possible chemotherapeutic applications in replacing
enzymes that are absent from individuals with certain genetic
disorders (DeYoung 1989).
Methods for Immobilisation
There are a number of ways in which an enzyme may be im-
mobilised: adsorption, covalent coupling, cross-linking, matrix
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Figure 7.19. A schematic representation of the most frequently used methods for DNA shuffling.
entrapment or encapsulation (Podgornik and Tennikova 2002;
Fig. 7.20). These methods will be discussed in the following
sections.
Adsorption
Adsorption is the simplest method and involves reversible
interactions between the enzyme and the support material
(Fig. 7.20A). The driving force causing adsorption is usually
the formation of several non-covalent bonds such as salt links,
Table 7.8. Advantages of Immobilised Enzymes
1. Repetitive use of a single batch of enzymes.
2. Immobilisation can improve enzyme’s stability by
restricting the unfolding of the protein.
3. Product is not contaminated with the enzyme. This is very
important in the food and pharmaceutical industries.
4. The reaction is controlled rapidly by removing the enzyme
from the reaction solution (or vice versa).
van der Waals, hydrophobic and hydrogen bonding (Calleri
et al. 2004). The methodology is easy to carry out and can be
applied to a wide range of support matrices such as alumina,
bentonite, cellulose, anion and cation exchange resins, glass,
hydroxyapatite, kaolinite, etc. The procedure consists of mixing
together the enzyme and a support under suitable conditions
of pH, ionic strength, temperature, etc. The most significant
advantages of this method are (i) absence of chemicals resulting
to a little damage to enzyme and (ii) reversibility, which allows
regeneration with fresh enzyme. The main disadvantage of the
method is the leakage of the enzyme from the support under
many conditions of changes in the pH, temperature and ionic
strength. Another disadvantage is the non-specific, adsorption
of other proteins or other substances to the support. This may
modify the properties of the support or of the immobilised
enzyme.
Covalent Coupling
The covalent coupling method is achieved by the formation
of a covalent bond between the enzyme and the support
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Figure 7.20. Representation of the methods by which an enzyme
may be immobilised: adsorption, covalent coupling, cross-linking,
matrix entrapment and encapsulation.
(Fig. 7.20B). The binding is very strong and therefore little
leakage of enzyme from the support occurs (Calleri et al. 2004).
The bond is formed between reactive electrophile groups present
on the support and nucleophile side chains on the surface of the
enzyme. These side-chains are usually the amino group (–NH2)
of lysine, the imidazole group of histidine, the hydroxyl group
(–OH) of serine and threonine, and the sulfydryl group (–SH)
of cysteine. Lysine residues are found to be the most gener-
ally useful groups for covalent bonding of enzymes to insoluble
supports due to their widespread surface exposure and high re-
activity, especially in slightly alkaline solutions.
It is important that the amino acids essential to the catalytic
activity of the enzyme are not involved in the covalent linkage to
the support (Dravis et al. 2001). This may be difficult to achieve,
and enzymes immobilised in this fashion generally lose activity
upon immobilisation. This problem may be prevented if the en-
zyme is immobilised in the presence of saturating concentrations
of substrate, product or a competitive inhibitor to protect active
site residues. This ensures that the active site remains ‘unre-
acted’ during the covalent coupling and reduces the occurrence
of binding in unproductive conformations.
Various types of beaded supports have been used successfully
as for example, natural polymers (e.g. agarose, dextran and cel-
lulose), synthetic polymers (e.g. polyacrylamide, polyacryloyl
trihydroxymethylacrylamide, polymethacrylate), inorganic (e.g.
silica, metal oxides and controlled pore glass) and microporous
flat membrane (Calleri et al. 2004).
The immobilisation procedure consists of three steps (Cal-
leri et al. 2004): (i) activation of the support, (ii) coupling of
ligand and (iii) blocking of residual functional groups in the
matrix. The choice of coupling chemistry depends on the en-
zyme to be immobilised and its stability. A number of meth-
ods are available in the literature for efficient immobilisation
of enzyme through a chosen particular functional side chain’s
group by employing glutaraldehyde, oxirane, cyanogen bro-
mide, 1,1-carbonyldiimidazole, cyanuric chloride, trialkoxysi-
lane to derivatise glass, etc. Some of them are illustrated in
Figure 7.21.
Cross-linking
This type of immobilisation is achieved by cross-linking the
enzymes to each other to form complex structures as shown
in Figure 7.20C. It is therefore a support-free method and less
costly than covalent linkage. Methods of cross-linking involve
covalent bond formation between the enzymes using bi- or multi-
functional reagent. Cross-linking is frequently carried out using
glutaraldehyde, which is of low cost and available in industrial
quantities. To minimise close proximity problems associated
with the cross-linking of a single enzyme, albumin and gelatin
are usually used to provide additional protein molecules as spac-
ers (Podgornik and Tennikova 2002).
Entrapment and Encapsulation
In the immobilisation by entrapment, the enzyme molecules are
free in solution, but restricted in movement by the lattice struc-
ture of the gel (Fig. 7.20D; Balabushevich et al. 2004). The
entrapment method of immobilisation is based on the locali-
sation of an enzyme within the lattice of a polymer matrix or
membrane (Podgornik and Tennikova 2002). It is done in such
a way as to retain protein while allowing penetration of sub-
strate. Entrapment can be achieved by mixing an enzyme with
chemical monomers that are then polymerised to form a cross-
linked polymeric network, trapping the enzyme in the intersti-
tial spaces of lattice. Many materials have been used, such as
alginate, agarose, gelatin, polystyrene and polyacrylamide. As
an example of this latter method, the enzymes’ surface lysine
residues may be derivatised by reaction with acryloyl chloride
(CH2 = CH–CO–Cl) to give the acryloyl amides. This product
may then be copolymerised and cross-linked with acrylamide
(CH2 = CH–CO–NH2) and bisacrylamide (H2N–CO–CH =
CH–CH = CH–CO–NH2) to form a gel.
Encapsulation of enzymes can be achieved by enveloping the
biological components within various forms of semipermeable
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Figure 7.21. Commonly used methods for the covalent
immobilisation of enzymes. (A) Activation of hydroxyl support by
cyanogen bromide. (B) Carbodiimides may be used to attach amino
groups on the enzyme to carboxylate groups on the support or
carboxylate groups on the enzyme to amino groups on the support.
(C) Glutaraldehyde is used to cross-link enzymes or link them to
supports. The product of the condensation of enzyme and
glutaraldehyde may be stabilised against dissociation by reduction
with sodium borohydride.
membranes as shown in Figure 7.20E. Encapsulation is most
frequently carried out using nylon and cellulose nitrate to con-
struct microcapsules varying from 10 to 100 μM. In general,
entrapment methods have found more application on the immo-
bilisation of cells.
New Approaches for Oriented Enzyme
Immobilisation: The Development
of Enzyme Arrays
With the completion of several genome projects, attention has
turned to the elucidation of functional activities of the encoded
proteins. Because of the enormous number of newly discovered
open reading frames, progress in the analysis of the correspond-
ing proteins depends on the ability to perform characterisation
in a parallel and high throughput format (Cahill and Nordhoff
2003). This typically involves construction of protein arrays
based on recombinant proteins. Such arrays are then analysed
for their enzymatic activities and the ability to interact with
other proteins or small molecules, etc. The development of en-
zyme array technology is hindered by the complexity of protein
molecules. The tremendous variability in the nature of enzymes
and consequently in the requirement for their detection and iden-
tification makes the development of protein chips a particularly
challenging task. Additionally, enzyme molecules must be im-
mobilised on a matrix in a way that they preserve their native
structures and are accessible to their targets (Cutler 2003). The
immobilisation chemistry must be compatible with preserving
enzyme molecules in native states. This requires good control
of local molecular environments of the immobilised enzyme
molecule (Yeo et al. 2004). There is one major barrier in en-
zyme microarray development: the immobilisation chemistry
has to be such that it preserves the enzyme in native state and
with optimal orientation for substrate interaction. This problem
may be solved by the recently developed in vitro protein liga-
tion methodology. Central to this method is the ability of certain
protein domains (inteins) to excise themselves from a precur-
sor protein (Lue et al. 2004). In a simplified intein expression
system, a thiol reagent induces cleavage of the intein–extein
bond, leaving a reactive thioester group on the C-terminus of
the protein of interest. This group can then be used to couple
essentially any polypeptide with an N-terminal cysteine to the
thioester tagged protein by restoring the peptide bond. In another
methodology, optimal orientation is based on the unique ability
of protein prenyl-transferases to recognise short but highly spe-
cific C-terminal protein sequences (Cys–A–A–X–), as shown
in Figure 7.22. The enzyme accepts a spectrum of phosphoiso-
prenoid analogues while displaying a very strict specificity for
the protein substrate. This feature is explored for protein derivati-
sation. Several types of pyrophosphates (biotin analogues, pho-
toreactive aside and benzophenone analogues; Fig. 7.22) can
be covalently attached to the protein tagged with the Cys-A-
A-X motif. After modification, the protein can be immobilised
directly either reversibly through biotin–avidin interaction on
avidin modified support or covalently through the photoreactive
group on several supports.
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Figure 7.22. Principal scheme of using CAAX-tagged proteins for covalent modification with prenyl transferases.
ENZYME UTILISATION IN INDUSTRY
Enzymes offer potential for many exciting applications in in-
dustry. Some important industrial enzymes and their sources are
listed in Table 7.9. In addition to the industrial enzymes listed
above, a number of enzyme products have been approved for
therapeutic use. Examples include tissue plasminogen activator
and streptokinase for cardiovascular disease, adenosine deami-
nase for the rare severe combined immunodeficiency disease, β-
glucocerebrosidase for Type 1 Gaucher disease, l-asparaginase
for the treatment of acute lymphoblastic leukemia, DNAse for
the treatment of cystic fibrosis and neuraminidase which is being
targeted for the treatment of influenza (Cutler 2003).
There are also thousands of enzyme products used in small
amounts for research and development in routine laboratory
practice and others that are used in clinical laboratory assays.
This group also includes a number of DNA- and RNA-modifying
enzymes (DNA and RNA polymerase, DNA ligase, restriction
endonucleases, reverse transcriptase, etc.), which led to the de-
velopment of molecular biology methods and were a foundation
for the biotechnology industry (Yeo et al. 2004). The clever ap-
plication of one thermostable DNA polymerase led to the PCR
and this has since blossomed into numerous clinical, forensic and
academic embodiments. Along with the commercial success of
these enzyme products, other enzyme products are currently in
commercial development.
Another important field of application of enzymes is in
metabolic engineering. Metabolic engineering is a new ap-
proach involving the targeted and purposeful manipulation of
the metabolic pathways of an organism, aiming at improving
the quality and yields of commercially important compounds.
It typically involves alteration of cellular activities by manipu-
lation of the enzymatic functions of the cell using recombinant
DNA and other genetic techniques. For example, the combina-
tion of rational pathway engineering and directed evolution has
been successfully applied to optimise the pathways for the pro-
duction of isoprenoids such as carotenoids (Schmidt-Dannert
et al. 2000, Umeno and Arnold 2004).
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Table 7.9. Some Important Industrial Enzymes and Their Sources
Enzyme EC Number Source Industrial Use
Rennet 3.4.23.4 Abomasum Cheese
α-Amylase 3.2.1.1 Malted barley, Bacillus, Aspergillus Brewing, baking
α-Amylase 3.2.1.2 Malted barley, Bacillus Brewing
Bromelain 3.4.22.4 Pineapple latex Brewing
Catalase 1.11.1.6 Liver, Aspergillus Food
Penicillin amidase 3.5.1.11 Bacillus Pharmaceutical
Lipoxygenase 1.13.11.12 Soybeans Food
Ficin 3.4.22.3 Fig latex Food
Pectinase 3.2.1.15 Aspergillus Drinks
Invertase 3.2.1.26 Saccharomyces Confectionery
Pectin lyase 4.2.2.10 Aspergillus Drinks
Cellulase 3.2.1.4 Trichoderma Waste
Chymotrypsin 3.4.21.1 Pancreas Leather
Lipase 3.1.1.3 Pancreas, Rhizopus, Candida Food
Trypsin 3.4.21.4 Pancreas Leather
α-Glucanase 3.2.1.6 Malted barley Brewing
Papain 3.4.22.2 Pawpaw latex Meat
Asparaginase 3.5.1.1 Erwinia chrisanthemy, Erwinia carotovora, Escherichia coli Human health
Glucose isomerase 5.3.1.5 Bacillus Fructose syrup
Protease 3.4.21.14 Bacillus Detergent
Aminoacylase 3.5.1.14 Aspergillus Pharmaceutical
Raffinase 3.2.1.22 Saccharomyces Food
Glucose oxidase 1.1.3.4 Aspergillus Food
Dextranase 3.2.1.11 Penicillium Food
Lactase 3.2.1.23 Aspergillus Dairy
Glucoamylase 3.2.1.3 Aspergillus Starch
Pullulanase 3.2.1.41 Klebsiella Starch
Raffinase 3.2.1.22 Mortierella Food
Lactase 3.2.1.23 Kluyveromyces Dairy
ENZYMES INVOLVED IN XENOBIOTIC
METABOLISM AND BIOCHEMICAL
INDIVIDUALITY
The term xenobiotic metabolism refers to the set of metabolic
pathways that chemically modify xenobiotics, which are com-
pounds foreign to an organism’s normal biochemistry, such as
drugs and poisons. The term biochemical individuality of xeno-
biotic metabolism refers to variability in xenobiotic metabolism
and drug responsiveness among different people. Biochemi-
cal individuality is a significant factor that can improve public
health, drug therapy, nutrition and health impacts such as cancer,
diabetes 2 and cardiovascular disease.
Most xenobiotics are lipophilic and able to bind to lipid mem-
branes and be transported in the blood (Hodgson 2004). The en-
zymes that are involved in xenobiotic metabolism (Table 7.10)
comprise one of the first defense mechanism against environ-
mental carcinogens and xenobiotic compounds (Zhang et al.
2009a). Xenobiotic metabolism follows mainly three phases (I,
II, III). In Phase I, the original compound obtain increased hy-
drophilicity and constitute an adequate substrate for phase II
enzymes, by the introduction of a polar reactive group (–OH,
–NH2, –SH or –COOH). In Phase II, the products of Phase I can
be conjugated to substrates such as GSH, which result in a sig-
nificant increase of water solubility of xenobiotic, promoting its
excretion (Hodgson 2004). The ATP-dependent transporters that
facilitate the movement of the polar conjugates (by phase I and
II) across biological membranes and their excretion from the cell
constitute Phase III proteins (Josephy and Mannervik 2006). In
general, the enzymes that are involved in xenobiotic metabolism
are genetically polymorphic, affecting the individual delicacy to
environmental pollutants (Zhang et al. 2009a).
Phase I
Human cytochrome P450, is one of the most important enzymes
that takes part in xenobiotic metabolism; therefore, its genetic
polymorphisms have been studied in depth. For example, P450
2A6 (CYP2A6) catalyses nicotine oxidation, and it has been
found to have inter-individual and inter-ethnic variability. Ge-
netic polymorphisms of this gene impact smoking behaviour
(Xu et al. 2002). Another example of genetic polymorphism’s
impact of this enzyme came from Siraj et al., who suggested
that CYP1A1 phenotype AA showed association with increased
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Table 7.10. The Main Enzymes Involved in Xenobiotic Metabolism
Reactions
Phase I enzymes
Cytochrome P450 (CYPs) Epoxidation/hydroxylation
N-, O-, S-dealkylation
N-, S-, P-oxidation
Desulfuration
Dehalogenation
Azo reduction
Nitro reduction
Flavin-containing monooxygenases (FMOs) N-, S-, P-oxidation
Desulfuration
Alcohol dehydrogenase Oxidation
Reductions
Aldehyde dehydrogenase Oxidation
Prostaglandin synthetase co-oxidation Dehydrogenation
N-dealkylation
Epoxidation/hydroxylation
Oxidation
Molybdenum hydroxylases Oxidation
Reductions
Esterases and amidases Hydrolysis
Epoxide hydrolase Hydrolysis
Phase II enzymes
UDP (uridine diphospho) glucuronosyl transferase
(UGT)
Glucuronide conjugation
Sulfotransferases Sulfation reaction
Sulfatases Hydrolysis of sulfate esters
Methyltransferases N-, O-, S-methylation,
Glutathione S-transferase Alkyltransferase, aryltransferase, aralkyltransferase,
alkenetransferase, epoxidetransferase
γ -Glutamyltranspeptidase Hydrolysis
Transpeptidation
N-acetyltransferase Acetylation
Aminopeptidases Hydrolysis of peptides
N,O-Acyltransferase Acylation
Cysteine conjugate β-lyase Methylation
Phase III enzymes
MRP (multi-drug resistance – associated protein)
MDR (multi-drug resistance family/P-glycoprotein)
MXR (mitoxantrone-resistance protein) efflux
Transport and excretion of soluble products from phase I and II
metabolic pathways
Source: Rommel and Richard 2002, Hodgson 2004, Josephy and Mannervik 2006.
risk of developing papillary thyroid cancer in Middle Eastern
population (Siraj et al. 2008).
Another studied genetic polymorphic enzyme is superoxide
dismutase-2 (SOD). The heterozygosity 9Val-allele of MnSOD
is associated with a higher risk and severity of orofaciolin-
gual dyskinesias (TDof) in Russian psychiatric inpatients from
Siberia (Al Hadithy et al. 2010). In addition, there are several
studies that have reported and showed that the 9Val/9Val geno-
type confer great susceptibility to tardive dyskinesia (Zhang
et al. 2003, Akyol et al. 2005, Galecki et al. 2006, Hitzeroth
et al. 2007). In addition, human MnSOD gene encoding alanine
(A) or valine at codon 16 (Shimoda-Matsubayashi et al. 1996)
can be a risk factor for several malignancies (Iguchi et al. 2009).
Phase II
Polymorphisms of human UGT correlate with diseases and side
effects of drugs, for example the isoform UGT1A1 is asso-
ciated with diseases of bilirubin metabolism (Hodgson 2004).
N-Acetyltransferases (NAT) are important enzymes that par-
ticipate in metabolic activation of carcinogenic aromatic and
heterocyclic amines that are present in cigarette smoke (Wang
P1: SFK/UKS P2: SFK
BLBS102-c07 BLBS102-Simpson March 21, 2012 11:12 Trim: 276mm X 219mm Printer Name: Yet to Come
7 Biocatalysis, Enzyme Engineering and Biotechnology 157
et al. 1999). An association was found between smokers with
MnSOD AA genotype and prostate cancer risk, especially in
case of rapid NAT1 subjects (Iguchi et al. 2009). Tamini et al.
found that the AA genotype of MnSOD in women smokers have
an elevated risk for breast cancer (Tamini et al. 2004).
Tobacco smoke (Lioy and Greenberg 1990) as well as smoked
foods, cereals, leafy green vegetables and fossil fuels combus-
tion by-products (Waldman et al. 1991) are the sources of expo-
sure to polycyclic aromatic hydrocarbons (PAHs). PAHs have
been considered as potential carcinogens for human (Shimada
2006). According to McCarty et al., the lack of dose–response
relationship of PAHs and breast cancer may be due to genetic
differences in metabolic activation and detoxification of PAHs
(McCarty et al. 2009).
Phase III
The proteins of phase III are membrane transporters. These pro-
teins seem to be significantly implicated in the absorption, distri-
bution and discard of drugs (Rommel and Richard 2002). There
are genetic polymorphisms of drug transporters, which appear to
have clinical impact and have been detected in multiple clinical
and in vitro studies (Maeda and Sugiyama 2008).
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